SEC Filing · 4
Equillium, Inc.
EQNASDAQEQUITYCurrent
SEC Filing
Company context
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗